iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells
Open Access
- 19 November 2009
- journal article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 8 (1), 108
- https://doi.org/10.1186/1476-4598-8-108
Abstract
Background: Doxorubicin is one of the few chemotherapeutic drugs able to exert both cytotoxic and pro-immunogenic effects against cancer cells. Following the drug administration, the intracellular protein calreticulin is translocated with an unknown mechanism onto the plasma membrane, where it triggers the phagocytosis of tumour cells by dendritic cells. Moreover doxorubicin up-regulates the inducible nitric oxide (NO) synthase (iNOS) gene in cancer cells, leading to huge amounts of NO, which in turn acts as a mediator of the drug toxicity and as a chemosensitizer agent in colon cancer. Indeed by nitrating tyrosine on the multidrug resistance related protein 3, NO decreases the doxorubicin efflux from tumour cells and enhances the drug toxicity. It is not clear if NO, beside playing a role in chemosensitivity, may also play a role in doxorubicin pro-immunogenic effects. To clarify this issue, we compared the doxorubicin-sensitive human colon cancer HT29 cells with the drug-resistant HT29-dx cells and the HT29 cells silenced foriNOS(HT29iNOS-).Results: In both HT29-dx and HT29iNOS-cells, doxorubicin did not induce NO synthesis, had a lower intracellular accumulation and a lower toxicity. Moreover the drug failed to promote the translocation of calreticulin and the phagocytosis of HT29-dx and HT29iNOS-cells, which resulted both chemoresistant and immunoresistant. However, if NO levels were exogenously increased by sodium nitroprusside, the chemosensitivity to doxorubicin was restored in HT29iNOS-cells. In parallel the NO donor per se was sufficient to induce the exposure of calreticulin and to increase the phagocytosis of HT29iNOS-cells by DCs and their functional maturation, thus mimicking the pro-immunogenic effects exerted by doxorubicin in the parental drug-sensitive HT29 cells.Conclusion: Our data suggest that chemo- and immuno-resistance to anthracyclines are associated in colon cancer cells and rely on a common mechanism, that is the inability of doxorubicin to induceiNOS. Therefore NO donors might represent a promising strategy to restore both chemosensitivity and immunosensitivity to doxorubicin in resistant cells.Keywords
This publication has 39 references indexed in Scilit:
- Immunogenic cell death modalities and their impact on cancer treatmentApoptosis, 2009
- Immunogenicity of anthracyclines: moving towards more personalized medicineTrends in Molecular Medicine, 2008
- Cyclical upregulated iNOS and long-term downregulated nNOS are the bases for relapse and quiescent phases in a rat model of IBDAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2006
- A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcriptionJournal of Molecular and Cellular Cardiology, 2005
- Novel effect of NF-κB activation: carbonylation and nitration injury to cytoskeleton and disruption of monolayer barrier in intestinal epitheliumAmerican Journal of Physiology-Cell Physiology, 2004
- Insulin Stimulates Glucose Transport Via Nitric Oxide/Cyclic GMP Pathway in Human Vascular Smooth Muscle CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Drug resistance reversal—are we getting closer?European Journal of Cancer, 2003
- Doxorubicin Induces an Increase of Nitric Oxide Synthesis in Rat Cardiac Cells That Is Inhibited by Iron SupplementationToxicology and Applied Pharmacology, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Nitric oxide and cell deathBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1999